GeneDx Holdings Corp SEC Filings

GeneDx Holdings Corp. reported that investment entities associated with Casdin Capital made open-market purchases of a total of 500,000 shares of Class A Common Stock. These buys occurred on May 18–20, 2026 at weighted average prices in the low-to-mid $40 range.

After these transactions, an investment fund managed by Casdin Capital reported holding 3,507,164 shares indirectly. Separate positions include 20,517 shares owned directly by Eli Casdin and other indirect holdings of 333,144 and 19,247 shares reported for related entities.

GeneDx Holdings Corp. reported substantial insider-related buying of its Class A Common Stock by investment funds advised by Corvex Management LP. These funds purchased a total of 351,273 shares in open-market transactions between May 13 and May 15 at weighted average prices within ranges from about $37.78 to $40.60 per share.

After these transactions, the Corvex-advised funds directly hold 4,784,570 shares. In addition, CMLS Holdings LLC holds 333,144 shares, over which Keith A. Meister shares voting and investment discretion, and Meister separately holds 20,129 shares issued upon vesting of restricted stock units for his board service.

GeneDx Holdings Corp. insiders Eli Casdin and Keith Meister report updated ownership positions in this Schedule 13D amendment. Based on 29,688,027 Shares outstanding as of May 1, 2026, Eli Casdin beneficially owns 3,599,671 Shares, representing 12% of the Class A common stock. Keith Meister beneficially owns 5,356,767 Shares, representing 17.9% of the class. These stakes include Shares held through entities such as CMLS Holdings LLC, Casdin Partners Master Fund, LP and investment funds advised by Corvex Management LP. Certain holdings include 204,141 private placement warrants exercisable at $379.50 per Share, fully vested options and restricted stock units granted for board service. The filing notes that recent trades by the reporting persons were executed as open market transactions.

GeneDx Holdings Corp. reported significant insider buying linked to director and ten percent owner Keith A. Meister. Investment funds advised by Corvex Management LP made open-market purchases totaling 1,205,147 shares of Class A Common Stock between May 7 and May 11, 2026, at weighted average prices generally in the mid-$30s to low-$40s per share. After these trades, the Corvex-advised funds directly held 4,433,297 shares of Class A Common Stock. The filing states Mr. Meister may be deemed to indirectly beneficially own these shares through his control of Corvex’s general partner, while both Corvex and Mr. Meister disclaim beneficial ownership beyond their pecuniary interest. The filing also notes 333,144 shares held of record by CMLS Holdings LLC, where Mr. Meister shares voting and investment discretion, and 20,129 shares issued to Mr. Meister upon vesting of restricted stock units for his board service.

GeneDx Holdings Corp. major shareholders Eli Casdin and Keith Meister have filed Amendment No. 10 to their Schedule 13D, updating their ownership and derivative positions in the company’s Class A common stock.

Based on 29,688,027 Shares outstanding as of May 1, 2026, Keith Meister is reported to beneficially own 5,005,494 Shares, representing 16.7% of the class, primarily through investment funds advised by Corvex Management LP and interests in CMLS Holdings LLC. Eli Casdin is reported to beneficially own 3,599,671 Shares, or 12.0% of the class, through Casdin-affiliated funds, CMLS Holdings LLC, and equity awards tied to his board service.

The amendment also describes cash-settled swaps entered into by Casdin Partners Master Fund, LP with Morgan Stanley, providing economic long exposure equivalent to a notional 850,000 Shares in total. These swaps are cash-settled only, confer no voting or dispositive power over GeneDx securities, and are expressly disclaimed as beneficial ownership.

GeneDx Holdings Corp. reported new derivative activity by Casdin-affiliated entities. Casdin Partners Master Fund, L.P. entered into open-market purchases of cash-settled swap agreements referencing GeneDx Class A common stock on three dates. On May 7, 2026, the Master Fund added swaps representing economic exposure to 500,000 notional shares at $38.1543 per share. On May 8, 2026, it added exposure to a further 300,000 notional shares at $41.0261 per share, and on May 11, 2026, to 50,000 notional shares at $39.6602 per share. After these transactions, the filing shows aggregate exposure of 850,000 notional shares through cash-settled swaps. The footnotes state these swaps provide economic results comparable to ownership but do not give the Master Fund voting or disposition power over GeneDx shares, and that the swaps are owned directly by the Master Fund and may be deemed indirectly beneficially owned by Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin.

GeneDx Holdings Corp. reported strong revenue growth but a sharply higher loss for the quarter ended March 31, 2026. Total revenue rose 17% to $102.3 million, driven by an 18% increase in diagnostic test revenue to $101.3 million as whole exome and genome volumes grew 34%.

Net loss widened to $63.3 million from $6.5 million a year earlier, or $2.16 per share, mainly due to $31.3 million of non‑cash impairment charges related to the Fabric Genomics unit and a $6.6 million loss on extinguishment of debt. Cash, cash equivalents and marketable securities totaled $170.7 million, helped by a new $100 million term loan from Blackstone, while operating cash flow was a $32.4 million outflow.

GeneDx Holdings Corp. reported first quarter 2026 revenue of $102.3 million, up 17% year-over-year, driven by strong demand for exome and genome testing. Exome and genome revenue rose to $90.6 million, a 27% increase, on 34% higher test volumes of 27,488.

Profitability weakened: GAAP net loss widened to $63.3 million, and adjusted net results shifted to an $8.2 million adjusted net loss from adjusted net income of $9.2 million a year earlier, despite an adjusted gross margin of 69%. The company ended March 31, 2026 with $171.7 million in cash, cash equivalents, marketable securities and restricted cash.

GeneDx cut its full‑year 2026 revenue guidance to $475–$490 million from $540–$555 million, while still targeting at least 30% growth in exome and genome volume, at least 20% growth in exome and genome revenue, approximately 70% adjusted gross margin, and positive adjusted net income for the year. Second quarter 2026 guidance calls for revenue of $110–$112 million, exome and genome revenue of about $100 million, roughly 30,000 exome and genome tests, approximately 70% adjusted gross margin, and an adjusted net loss of about $5 million.

GeneDx Holdings Corp. chief executive officer Katherine Stueland reported routine equity compensation activity involving restricted stock units and related tax sales. On April 29, 2026, 3,874 restricted stock units converted into the same number of shares of Class A Common Stock for no cash consideration, increasing her direct holdings.

The filing also shows open-market sales totaling 2,172 shares of Class A Common Stock at prices around the mid‑$60s per share to cover tax withholding obligations from the RSU vesting. A footnote states this was a “sell to cover” transaction and “does not represent a discretionary transaction.” Following these sales, she beneficially owned 93,216 shares of Class A Common Stock, plus RSUs for up to 330,821 additional shares and options to purchase up to 107,610 shares, all vesting under their existing schedules.